Chief Strategy Officer Nathan Buchbinder predicts precision medicine business unit will gain more prominence at pharmaceutical and biotechnology companies this year.
Chief Strategy Officer Nathan Buchbinder predicts precision medicine business unit will gain more prominence at pharmaceutical and biotechnology companies this year.